GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market

The FDA has approved GSK's Penmenvy, a 5-in-1 meningococcal vaccine for individuals aged 10 to 25 years13.

Penmenvy protects against meningococcal serogroups A, B, C, W, and Y, which cause the majority of invasive meningococcal disease (IMD) cases globally13.

The vaccine combines components from GSK's existing vaccines Bexsero (MenB) and Menveo (MenACWY)13.

Penmenvy is administered as a two-dose series, with doses given six months apart1.

GSK's approval follows Pfizer's Penbraya, which was approved in 2023 as the first 5-in-1 meningococcal vaccine in the U.S. market1.

The current vaccine uptake for meningococcal vaccines is relatively low, with only 32% of adolescents starting the MenB vaccination series and less than 13% completing it1.

By 2030, Penmenvy is forecasted to achieve blockbuster sales of $1.1 billion worldwide, compared to $606 million for Pfizer's Penbraya1.

The approval of Penmenvy aims to simplify the meningococcal vaccination schedule and potentially improve coverage rates13.

Invasive meningococcal disease can be fatal within 24 hours of onset, making prevention through vaccination crucial13.

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) is expected to discuss recommendations for Penmenvy at its next meeting on February 26, 20251.

Sources:

1. https://www.fiercepharma.com/pharma/gsk-joins-pfizer-5-1-meningococcal-vaccine-ring-fda-approval

3. https://outbreaknewstoday.substack.com/p/5-in-1-meningococcal-vaccine-penmenvy